Is there a future for mRNAs as viral vaccines?

Affiliations

¹ Centre for Clinical Vaccinology & Tropical Medicine, Churchill Hospital, Oxford Vaccine Group, University of Oxford, Oxford, OX3 7LE, UK. Electronic address: mary.warrell@ndm.ox.ac.uk.

Comment

Mary Warrell. Lancet. 2017.

. 2017 Sep 23;390(10101):1470-1471.

doi: 10.1016/S0140-6736(17)31964-5. Epub 2017 Jul 25.

¹ Centre for Clinical Vaccinology & Tropical Medicine, Churchill Hospital, Oxford Vaccine Group, University of Oxford, Oxford, OX3 7LE, UK. Electronic address: mary.warrell@ndm.ox.ac.uk.

No abstract available

Comment on

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.
Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD, Fotin-Mleczek M, Hoerr I, Clemens R, von Sonnenburg F. Alberer M, et al. Lancet. 2017 Sep 23;390(10101):1511-1520. doi: 10.1016/S0140-6736(17)31665-3. Epub 2017 Jul 25. Lancet. 2017. PMID: 28754494 Clinical Trial.